Company intelligence / Profile preview

Vidara Therapeutics

Ownership: Private
Development stage: Commercial

Overview

Vidara Therapeutics was a specialty pharmaceutical company focused on rare diseases and orphan drug therapies. Its lead product, ACTIMMUNE (interferon gamma‑1b), was FDA-approved for chronic granulomatous disease and severe malignant osteopetrosis. The company achieved commercial success with ACTIMMUNE, recording $58.9 million in net sales in 2013 before being acquired by Horizon Pharma[1][2][6].

Therapeutic areas: ImmunologyRare Diseases
Modalities: Biologics (notably interferon gamma-1b)
Industry: Biotech

Drug pipeline

1 asset

interferon gamma-1b

Commercial

Indications: Chronic granulomatous disease, Severe malignant osteopetrosis

Partnerships

DFW Capital Partners supported the acquisition of Actimmune® and growth initiatives[2].

Beyond the preview

Go deeper on Vidara Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vidara Therapeutics.

Explore the full profile